Solution Speeds Targeted Therapies

Positive Select is a comprehensive genomic solution for solid tumors(Lung Cancer, breast Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma etc) as well as Haematological cancers(leukaemia, lymphoma, myeloma) designed to provide oncologists with clinically actionable report which can identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials.

The test employs RNA sequencing to detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.

Positive Select test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. Report provides treatment options with best probability of working in a particular patient based on cancer driving pathways and information on on-going clinical trials. Report also come with expression data of around 25,000 genes and thus is the most advanced test available in the world.

“RNA sequencing is fast replacing conventional molecular diagnostics globally and most of the leading cancer hospitals and academic institutes in USA have started using RNA sequencing in clinical practice. It is a major step up as it removes conventional trial and error treatment approach leading to better outcomes and huge savings in treatment cost. Our experiences have showed that RNA sequencing in cancer can reduce treatment costs by 35%,” added Dr Santosh Mishra, Director of Bioinformatics, VGTI, Florida, USA and Scientific Advisor, Positive Bioscience.

Positive Select will be available in all leading hospitals of the country on a prescription of Oncologists.

Positive Bioscience Ltd.,+91 1800 3070 6727, www.positivebioscience.com